APA (7th ed.) Citation

T, M., I, K., MA, L., H, H., Y, U., T, M., . . . J, T. (2026). CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL. Cell reports. Medicine, 7(2), 102576. https://doi.org/10.1016/j.xcrm.2025.102576

Chicago Style (17th ed.) Citation

T, Mikami, et al. "CAR-T Cells with the CD38-CD73-Tim-3-HLA-DR+ Phenotype Predict the Efficacy of Tisagenlecleucel as a Treatment for B Cell Precursor ALL." Cell Reports. Medicine 7, no. 2 (2026): 102576. https://doi.org/10.1016/j.xcrm.2025.102576.

MLA (9th ed.) Citation

T, Mikami, et al. "CAR-T Cells with the CD38-CD73-Tim-3-HLA-DR+ Phenotype Predict the Efficacy of Tisagenlecleucel as a Treatment for B Cell Precursor ALL." Cell Reports. Medicine, vol. 7, no. 2, 2026, p. 102576, https://doi.org/10.1016/j.xcrm.2025.102576.